EMA Begins Review of Rucaparib After Finding of Shorter Survival EMA Begins Review of Rucaparib After Finding of Shorter Survival

Recently published results from the ARIEL4 trial show a significantly longer progression-free survival; but new results show a shorter overall survival.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news